 Research article
 Open Access
 Published:
Model composition through model reduction: a combined model of CD95 and NFκB signaling pathways
BMC Systems Biology volume 7, Article number: 13 (2013)
Abstract
Background
Many mathematical models characterizing mechanisms of cell fate decisions have been constructed recently. Their further study may be impossible without development of methods of model composition, which is complicated by the fact that several models describing the same processes could use different reaction chains or incomparable sets of parameters. Detailed models not supported by sufficient volume of experimental data suffer from nonunique choice of parameter values, nonreproducible results, and difficulty of analysis. Thus, it is necessary to reduce existing models to identify key elements determining their dynamics, and it is also required to design the methods allowing us to combine them.
Results
Here we propose a new approach to model composition, based on reducing several models to the same level of complexity and subsequent combining them together. Firstly, we suggest a set of model reduction tools that can be systematically applied to a given model. Secondly, we suggest a notion of a minimal complexity model. This model is the simplest one that can be obtained from the original model using these tools and still able to approximate experimental data. Thirdly, we propose a strategy for composing the reduced models together. Connection with the detailed model is preserved, which can be advantageous in some applications. A toolbox for model reduction and composition has been implemented as part of the BioUML software and tested on the example of integrating two previously published models of the CD95 (APO1/Fas) signaling pathways. We show that the reduced models lead to the same dynamical behavior of observable species and the same predictions as in the precursor models. The composite model is able to recapitulate several experimental datasets which were used by the authors of the original models to calibrate them separately, but also has new dynamical properties.
Conclusion
Model complexity should be comparable to the complexity of the data used to train the model. Systematic application of model reduction methods allows implementing this modeling principle and finding models of minimal complexity compatible with the data. Combining such models is much easier than of precursor models and leads to new model properties and predictions.
Background
Systems biology aims to study complex interactions in living systems and focuses on analysis and modeling their properties. Mathematical modeling provides several ways to describe biological processes based on experimental information of different kind. However, creation of detailed models not supported by enough experimental data often makes their analysis and interpretation difficult [1]. Several aspects of the same process can be modeled using different levels of abstraction involving different reaction chains, chemical kinetics, and incomparable sets of parameters. Such models are difficult to merge. Meanwhile, merging is an important approach for creation of complex models. Thus, development of efficient methods and software, allowing us to combine models, is the object of intense study in systems biology. In our work, we focused on the fact that, generally, complexity of models is not comparable to the volume of experimental data used to adjust their parameters. Due to this fact, we turn to the methods of model reduction allowing us to minimize model’s complexity without affecting the model simulation dynamics.
Model reduction is a wellestablished technique in many fields of biochemical research and engineering. It has been used for many years in chemical kinetics (for reviews, see [2–4]) and has already found multiple applications in systems biology, including discrete modeling [5] and modeling of metabolic pathways [6, 7]. The principles of this technique have been applied in computational biology [8] and implemented as a part of widely used pathway simulators such as BioUML [9], BIOCHAM [10], COPASI [11], and GINsim [12]. Model reduction led to new insights in mechanisms of translation regulation by microRNAs [13, 14] and was applied for analysis of such signaling pathways as JAKSTAT [15], NFκB [16], and EGFR [17].
In our investigation, we used the principles of model reduction to construct reasonably accurate minimal size approximations of two different models describing the CD95 signaling pathways [18, 19]. The first model explores proapoptotic properties of CD95 after stimulation by its natural ligand CD95L or by agonistic antibodies antiCD95 implying formation of the deathinducing signaling complex (DISC) [18, 20]. DISC consists of oligomerized CD95, death domaincontaining adaptor FASassociated molecule (FADD), procaspases8 and −10, and two isoforms of cellular FLIP (CFLAR) protein (cFLIP long and cFLIP short). Caspase8 leads to activation of effector caspase3 directly (type I cells) or via stimulation of cytochrome C release from the mitochondria (type II cells) [21]. The latter step requires formation of the apoptosome complex and activation of caspase9. Once activated, caspase3 cleaves poly(ADPribose) polymerase (PARP), thereby making the apoptotic process irreversible. The second model describes the state when CD95 not only activates the proapoptotic pathway, but also induces transcription factor NFκB that is an important regulator of cell survival functioning [19]. This is possible due to cFLIPL cleavage in the DISC complex. The cleaved p43FLIP directly interacts with the IKK complex and activates it. The activated IKK performs phosphorylation of the IκB protein and thereby frees NFκB.
The authors of the models have evaluated concentration changes of major apoptotic molecules by Western blot analysis and represented them as relative values at given time points. Using the systematic methodology [2] implemented in the BioUML software, we reduced the models so that they still satisfy these data. This allowed us to simplify the overlapping components of the models and find a way for their composition.
Methods
Model reduction
Mathematical modeling of biological processes based on the classical theory of chemical kinetics assumes that a model consists of a set of species S = (S_{1,…,}S_{ m }) associated with a set of variables C(t) = (C_{1}(t), …, C_{ m }(t)) depending on time t ∈ [0, T], T ∈ R^{+} and representing their concentrations, and a set of biochemical reactions with rates v(t) = (v_{1}(t), …, v_{ n }(t)) depending on a set of kinetic constants K. Reaction rates are modeled by massaction or MichaelisMenten kinetics. A system of ordinary differential equations (ODE) representing a linear combination of reaction rates is used to describe the model behavior over time:
Here N is a stoichiometric matrix of n by m. We say that C^{SS} is a steady state of the system (1) if
Model reduction implies transformation of the ODE system to another one with smaller number of equations without affecting dynamics of variables C_{1}(t), …, C_{ s }(t), which is fixed by a set of experimental pointsC_{ i }^{exp}(t_{ ij }) at given times t_{ ij }, j = 1, …, r_{ i }, where r_{ i } is number of such points for the concentration C_{ i }(t), i = 1, …,s. To check dynamics preservation in the course of model reduction, we consider the function of deviations defined as a normalized sum of squared differences [11]:
where ${\omega}_{\mathit{min}}=\underset{\mathit{\text{i}}}{\mathit{\text{min}}}{\omega}_{i},$ weights ${\omega}_{i}=\sqrt{{r}_{i}^{1}\xb7{\displaystyle \sum}_{j}{\left({C}_{i}^{\mathit{exp}}\left({t}_{\mathit{ij}}\right)\right)}^{2}}$ are calculated as mean squared values of experimental concentrations for each variable and the normalizing factor ω_{ min }/ω_{ i } is used to make all concentration trajectories to have similar importance.
Reducing kinetic model is possible when some quantities are much smaller than other quantities and can be neglected. Usually, this implies some qualitative relations (much bigger, much smaller) between model parameters. When these relations satisfy certain rules, we can approximate the detailed model by a simpler one. If the parameters are (approximately) determined, as in our case, we find an approximation specific for a region of the parameter space. However, if we want to investigate the model behavior for the entire space, we need to decompose it into regions characterized by asymptotically different behaviors of the dynamical systems. Afterwards, a specific reduction should be performed for each region (Figure 1).
We define the minimal complexity model as a reduced model with the minimal number of elements (species and reactions) so that the deviation function value (3) calculated for the reduced model is different from the original model no more than 20%. Such threshold is explained by the fact that in this work we considered experimental data obtained by Bentele et al.[18] and Neumann et al.[18] using Western blot technology with the standard deviation 1520%.
Reduction of mathematical model complexity is achievable by different methods [2]. Description of the methods directly used in our work is provided below.
(MR1) Removal of slow reactions. We say that reaction r_{1} is much slower than reaction ${r}_{2},{v}_{{r}_{1}}\left(t\right)\ll {v}_{{r}_{2}}\left(t\right)$ if $\underset{\mathit{\text{t}}}{\mathit{\text{max}}}\left{v}_{{r}_{1}}\left(t\right)\right<k\xb7\underset{\mathit{\text{t}}}{\mathit{\text{max}}}\left{v}_{{r}_{2}}\left(t\right)\right$, where k=10^{2}. When such reactions do not affect experimental dynamics of species, we neglect them. Note, that in some cases, it is sufficient to consider k = 10^{−1} or even k = 1.
(MR2) Quasisteadystate approximation[22] assumes that all variables C(t) of the model are split in two groups: basic variables C^{s}(t) and quasistationary variables C^{f}(t) for which we could write:
where ɛ is small parameter. We consider the approximation ɛ → 0 resulting in the equation N^{f} · v^{f}(C, K, t) = 0. Thus, the chain of reactions S → I → P with a quasistationary species I can be reduced to the form S → P.
(MR3) Lumping analysis refers to reducing the number of model variables by grouping some species. In particular, this can be illustrated by reactions
with kinetic rates ${v}_{r1}\left(t\right)={k}_{1}\xb7{C}_{A}\left(t\right)\xb7{C}_{{S}_{1}}\left(t\right)$ and ${v}_{r2}\left(t\right)={k}_{2}\xb7{C}_{A}\left(t\right)\xb7{C}_{{S}_{2}}\left(t\right)$. If k_{1} = k_{2} and ${C}_{{S}_{1}}\left(t\right)={C}_{{S}_{2}}\left(t\right)$, then the system (4) can be replaced by a single reaction
where ${C}_{S}\left(t\right)={C}_{{S}_{1}}\left(t\right)={C}_{{S}_{2}}\left(t\right)$, ${C}_{P}\left(t\right)={C}_{{P}_{1}}\left(t\right)={C}_{{P}_{2}}\left(t\right)$ and k = k_{1} = k_{2}. Note, that in this example lumped variables ${C}_{{S}_{1}}\left(t\right)$, ${C}_{{S}_{2}}\left(t\right)$ and ${C}_{{P}_{1}}\left(t\right)$, ${C}_{{P}_{2}}\left(t\right)$ are linearly dependent: however, this is not required in general case. For conditions on lumpability in monomolecular reaction networks, see [23].
(MR4) Removal of approximately linearly dependent variables. If variables A(t) and B(t) (species concentrations or reaction rates of the model) are approximately linearly dependent:
then we can replace one of them with another in all kinetic laws of the model.
(MR5) Simplification of the MichaelisMenten kinetics. Consider a reaction r of the form S –E → P, where an enzyme E converts a substrate S into product P. Reaction rate of such reaction is frequently defined by the MichaelisMenten formula
where the enzyme concentration is a dynamic variable allowing to use the same kinetics in different regions of the phase space. If Km ≫ C_{ S }(t), then we can reduce this formula to the form: ${v}_{r}\left(t\right)=\frac{k\xb7{C}_{S}\left(t\right)\xb7{C}_{E}\left(t\right)}{\mathit{Km}}$. On the other hand, if C_{ S }(t) ≫ Km, then (5) can be replaced by the equation v_{ r }(t) = k · C_{ E }(t).
(MR6) Simplification of equations based on the law of mass action when one reactant dominates others. Consider a reaction r of the form S_{1} + S_{2} → P with the kinetic law
When ${C}_{{S}_{1}}\left(t\right)\gg {C}_{{S}_{2}}\left(t\right)$ for t ∈ [0, T], the formula (6) can be replaced by the linear equation ${v}_{r}\left(t\right)=k\xb7{C}_{{S}_{1}}\left(0\right)\xb7{C}_{{S}_{2}}\left(t\right)$. The time T of validity of such pseudolineary approximation is defined as a period during which the relative change of ${C}_{{S}_{1}}\left(t\right)$ does not exceed some ε, i.e. $k\underset{0}{\overset{T}{{\displaystyle \int}}}{C}_{{S}_{2}}\left(t\right)\mathit{dt}<\mathit{\epsilon}$.
One way to perform the model reduction is to apply the foregoing methods in the numerical order (Figure 2). Note that the methods MR5 and MR6 are of the same type, so it does not matter which one to use first. This way assumes that we calculate the value of the distance function (3) at each reduction step to test whether approximation of the experimental data is still within allowable limit or not.
Model analysis and comparison
Model comparison using Akaike information criterion (AIC). This criterion [24] defines the relative complexity of a model based on the goodness of experimental data fit and the number of model parameters K (initial concentrations of species are not considered):
The function χ^{2} is defined by the formula (3) with weights 1/σ_{ ij }^{2} (instead of ω_{ min }/ω_{ i }) [15], where mean deviations σ_{ ij } of experimental values C_{ i }^{exp}(t_{ ij }) are calculated using smoothing spline [25]:
For j + k < 0 and j + k > r_{ i } we assumed C_{ i }(t_{i,j+k}) = C_{ i }^{exp}(t_{i,j+k}) = 0.
Models can be compared using the Akaike criterion, if they approximate the same experimental data. When the AIC value of one model is less than of others, we say that this model is simpler in terms of this criterion.
Model comparison with the mean AIC. When we want to compare models approximating different sets of experimental data, we could calculate the mean AIC coefficients by the formula
where n_{ exp } determines the number of experimental points.
Steadystate analysis finds values of species concentrations according to the rules (2). It is desirable to reduce a model so that steadystate concentrations of all experimentally measured chemical species have not changed significantly.
Sensitivity analysis reveals steadystate concentrations response to parameter perturbations. The local sensitivities C_{ i }^{ss}, i = 1, …, m, for all parameters p_{ j }, j = 1, …, K, are calculated via finite difference approximations:
It is useful to compute the mean log sensitivity for all fitted species:
where n_{ p } is the number of all parameters K or the number of parameters retained after the model reduction.
Modular modeling
Considering the mathematical models of CD95 signaling pathways [18, 19], we decomposed them into functional modules. This step allowed us to identify overlapping components of the models and simplify their analysis. We defined a module as a submodel (including several species, reactions and parameters of the model) with input, output and contact ports. The first two types of ports characterized variables calculated in one module and passed to another through a directed connection. The contact ports declared common variables of modules via undirected connections (for more details of modular modeling, see [26]).
Results
Preliminary analysis, problems and inconsistencies in the precursor models
The mathematical model by Bentele et al. (Figure 3A) consists of 43 species including a virtual variable x_{ aa } intended for quantification of “apoptotic activity” caused by active caspases3, 6 and 7 and calculated by the formula
where k_{36act}, k_{7act}, Km_{367act} ∈ K. The variable x_{ aa } specifies a process of degradation in the model introduced as an exponential decay function f_{ degr }(x_{ aa }). This function is defined by the formula k_{ d } · x_{ aa }^{2} + k_{ ds } with k_{ d },k_{ ds } ∈ K for all active caspases and complexes containing their cleaved products, and by the formula k_{ d } · x_{ aa }^{2} for all other molecules besides cPARP (cleaved PARP), where f_{ degr }(x_{ aa }) is constant. All species in the model are degraded with the exception of cytochrome C and Smac stored in the mitochondria, whose concentrations are constant.
In total, the model contains 80 reactions (Table 1) including 24 reactions based on mass action kinetics, 12 reactions taken with kinetics of MichaelisMenten, 41 reactions of degradation, the reaction of x_{ aa } production specified above and two reactions of cytochrome C and Smac release from the mitochondria modeled using a discrete event. The latter implies complete cytochrome C and Smac release within 7 minutes as soon as tBid reaches a certain level in comparison to Bcl2/BclXL. Since the authors did not provide exact form of the release function, we proposed the sigmoid function which has the expected behavior:
where t_{ trigger } is the time when tBid concentration reaches a value of Bcl2/BclXL, t_{ release } is the start time of release and k_{ contr } is the contraction coefficient.
The model comprises 43 species (including x_{ aa }) and 45 kinetic parameters, which the authors estimated based on the experimental data obtained by Western blot analysis for the human cell line SKW 6.4. Cells were stimulated by 5 μg/ml and 200 ng/ml of antiCD95 (fast and reduced activation scenarios, respectively) and dynamics of several proteins (Bid, tBid, PARP, cPARP, procaspases2, 3, 7, 8, 9, cleaved product of procaspase8 p43/p41, and caspases8) were measured.
We could not reproduce the dynamics of the original model using the parameter values provided by the authors. In particular, there was too rapid consumption of procaspases2, 3, 7, 8 in the case of 5 μg/ml of antiCD95 and procaspases2, 9 in the case of 200 ng/ml. Degradation rates of procaspase8 and caspases8 was insufficient for both activation scenarios. Thus, we had to make several modifications of the original model to obtain the same dynamics as described in the original paper. Namely, we multiplied the rate constants of all the bimolecular reactions by the value 5∙ 10^{5} and specified k_{ d } equal to 3.56 min^{1} and 0.62 min^{1} (instead of 0.891 min^{1} and 0.184 min^{1}) for fast and reduced activation scenarios, respectively.
The model by Neumann et al. includes 23 species, 23 reactions constructed according to the law of mass action, and 17 kinetic parameters (Figure 4A). It reproduces experimental measurements of 8 entities (total amount of procaspase8, its cleaved product p43/p41, caspase8, procaspase3, caspase3, IκBα, phosphorylated IκBα and cleaved p43FLIP) obtained using Western blot technology for HeLa cells stably overexpressing CD95–GFP and treated with three different concentrations of agonistic antiCD95 antibodies (1500, 500 and 250 ng/ml). This is the reduced model suggested by the authors for description of the CD95mediated pathways of cell death and NFκB activation. Model reduction was based on intuition about what is important in the biochemical mechanisms. It was performed as long as the parameter estimation procedure (repeated after each step of the reduction) was able to provide a good fit of the experimental data. Particularly, the details of some complex formations were omitted as well as some nonmeasured species were removed. The authors submitted the model to the BioModels database [27]. Thus, we had no problems reproducing it.
Reduction of the CD95signaling model
We started the Bentele’s model reduction by excluding the direct dependence of the virtual species x_{ aa } on caspases6 and 7. For this purpose, we approximated the amount of caspases7 by the linear function of caspase3 concentration:
where a = 0.18 for both activation scenarios. In addition, we considered inequalities holding for the parameters in the formula (10):
and simplified it:
After that we decomposed the model into modules (Figure 3B) corresponding to three biological steps: activation of caspase8, cytochrome Cinduced activation of caspase9 and PARP cleavage downregulated by these caspases.
Below we provide detailed description of the reduction process of all modules. The process is based on the flow chart represented in the Figure 2. If it is enough for a reader to have a general idea of model reduction without going into full details, we suggest to go directly to the last two paragraphs of this section, where you find the summary of the model reduction procedure.
Caspase8 activation module includes 20 species and 14 reactions (besides the reactions of degradation), which could be divided into three groups: cleavage of procaspase8 at the DISC complex, its activation triggered by caspase3, and inhibition of complexes containing DISC by cFLIPL and cFLIPS (Table 1, Figure 3A, reactions br1br14).
Firstly, we eliminated slow reactions br12 and br13 according to the method MR1. Next, we applied the quasisteadystate analysis (MR2) to the module and removed quasistationary intermediates CD95R:CD95L, DISC:pro8, DISC:pro8_{2}, DISC:p43/p41 and DISC:cFLIPL. Thus, in particular, we got two main reactions instead of br1br6: fast formation of the DISC complex (Table 1, Figure 3B, br1*) and slower activation of caspase8 in this complex (br2*).
Further, we noticed that the consumptions of cFLIPL and cFLIPS satisfied the same kinetic laws. Therefore, these species could be lumped (MR3) resulting in the reaction br4*:
cFLIP + 2∙ DISC + pro8 → cFLIP:DISC:pro8,
where cFLIP indicated two isoforms cFLIPL and cFLIPS so that C_{ cFLIP } = C_{ cFLIPL } = C_{ cFLIPS }.
We approximated the concentration of caspase6 by the linear function b · C_{casp3}, b = 0.145 (MR4), and merged reactions br7 and br8 of caspases8 activation induced by caspases3 and mediated by caspases6 into one reaction br3*:
pro8 –casp3 → casp8.
Since the reaction br8 followed the MichaelisMenten kinetics with the constants k_{68} and Km_{68}, then the reaction rate of br3* was provided by the kinetic law
where k_{38} = 0.145 · k_{68} and Km_{38} = Km_{68}. Analysis of this kinetic law for low level of CD95L ensured that C_{pro8} ≫ Km_{38}. In addition, in the case of the fast activation scenario the value of v_{ br3* } was much lower than the rate of caspase8 activation mediated by CD95. Thus, we established v_{ br3* } = k_{ 38 }·C_{ casp3 } without significant changes in the results of the model simulation (MR1, MR5).
Complementing the above reduction steps, we removed the elements that were unnecessary to fit the experimental dynamics provided by Bentele et al. These elements were degradation reactions of CD95L, CD95R and FLIP, and the blocked DISC complex (inactivated DISC). As a result, we introduced the conservation law:
where L_{0} and R_{0} denote initial concentrations of the ligand and receptor, respectively. Solving the differential equation
we obtained the analytical function for the receptor concentration:
The module of caspase9 activation consisted of 19 species and 14 reactions (besides the reactions of degradation) including activation of caspase9 triggered by cytochrome C, cleavage/activation of Bid by caspases2 and 8, IAP inhibition of caspase9 activity and binding of inhibitors by Smac (br15br26, br35, br38). Based on the method MR1, we eliminated the last two reversible reactions, as well as the slow reaction br20 of the apoptosome complex dissociation. Further, since this complex was a quasistationary intermediate and the rate of br15 was linearly dependent on a difference of br16 and br17 rates, we reduced the chain of procaspase9 activation (br15br20), using the methods MR2 and MR4, to the form:
Accordingly to Bentele et al., we have the following rule of cytochrome C release from mitochondria:
Here f_{ release }(t) satisfies the formula (11). Taking into account (15) and ignoring degradation of the complex Cyt C:Apaf1, we got
where c = 0.59 was the coefficient of linearity.
Then, we noticed that the experimental measurements of procaspase9 concentration were presented by Bentele and his colleagues only for 200 ng/ml of antiCD95. In this case, degradation of procaspase9 was insignificant. Thus, neglecting it and considering the kinetic law k_{ Apop }·C_{ pro9 }·C_{ CytC:Apaf1 } of the second reaction in (15), we obtained the differential equation of procaspase9 dynamics:
Solving it, we found:
Finally, analyzing reactions of Bid activation (br21br23), we removed the slower reaction mediated by caspase2. The similar reaction involving caspase8 followed the MichaelisMenten kinetics with the constant Km_{28Bid} ≫ C_{ Bid }. Therefore, we redefined the kinetics of this reaction based on the law of mass action (MR5):
The module of PARP inactivation contained 13 species (including the virtual species x_{ aa }) and 11 reactions (excepting reactions of degradation). Six reactions (activation of caspases3 and 7 by caspases8 and 9, and cleavage/inactivation of PARP) were based on the MichaelisMenten kinetics (br27br32), four reactions reproduced the reversible inhibition of caspases3 and 7 based on the law of mass action (br33, br34, br36, br37), and one corresponded to the production of x_{ aa } (br38), simplification of which was discussed above.
We deleted slow reactions of casp3:IAP and casp7:IAP complexes dissociation and ignored slow degradation of procaspase7 and IAP. Then analyzing the cleavage of procaspases3 and 7, we eliminated reactions triggered by caspase9, which were slower in comparison to the similar reactions induced by caspase8. For the same reason we ignored the reaction of PARP inactivation by caspase3 (MR1).
Considering the remaining reactions with the MichaelisMenten kinetics (br29, br32), we used the following inequalities Km_{78} ≫ C_{pro7} and Km_{376act} ≫ C_{ PARP }, which, in combination with MR5 and (12), led to the following kinetic laws:
where k_{ 3act } = 0.18 · k_{ 7act }
Thus, the CD95signaling model consisting of 43 species (including one virtual species), 80 reactions and 45 kinetic parameters was approximated by a model with 18 species, 26 reactions and 25 parameters, except the constant concentration of Cytochrome C (Figure 3C). Figure 5 shows the comparison of simulated concentrations of these models with experimental dynamics obtained by Bentele et al. for the 11 species mentioned above. Since this dynamics was expressed in arbitrary units, we uniquely translated it into precise values for all proteins with nonzero initial values. However, for such molecules as caspase8, p43/p41, tBid and cPARP, precise values directly depended on the concentration levels at the end or in the middle of time series. Accordingly, we computed these levels during the model reduction and recalculated experimental dots if necessary.
Species without experimental evidence (CD95L, DISC, cFLIP, DISC:pro8:cFLIP, IAP, caspase3 and virtual species x_{ aa }) and reactions br1*br13* directly affect the simulated dynamics of the experimentally measured concentrations (Table 2). Thus, further reduction of the model by removing these elements is impossible. Regarding the degradation process, we agree with Bentele et al. that experimental data cannot be matched if this process is fully ignored. Actually, if we remove any of the retained reactions of degradation, then excepted concentration dynamics will be impaired. Thus, we found the minimal complexity approximation of the original model.
Reduction of the CD95mediated and NFκB signaling model
As was mentioned above, Neumann et al. simplified their model in order to reduce the large number of free parameters. The authors noted that further simplification of the model was not possible because the model fit significantly decreased. However, we removed slow reactions (nr4, nr11nr13, Figure 4A) using the method MR1, and removed the reaction of NFκB degradation (nr23), which was not significant for reproducing the experimental data of the original model. Note that we retained the slow reactions nr6 and nr7, the former of which regulates apoptosis inhibition in the case of high levels of cFLIPL and procaspase8 in accordance with the precursor model prediction (see the analysis of the predictions below), and the latter of which will be required to combine this model with the Bentele’s model hereafter.
Based on the method MR6, we also took into account the inequality C_{ IKK } ≫ C_{p43−FLIP} and simplified the kinetic law
of the reaction nr19 to the form
Therefore, we reduced the number of model species from 23 to 20, the number of reactions from 23 to 18 and the number of kinetic parameters from 17 to 15 (besides the constant concentration of IKK). These modifications did not change the fit to the experimental data provided by Neumann et al. (Figure 6).
Model composition
Analysis of the reduced models based on the Akaike criterion (7) confirmed that they had lower complexity than the original models (Table 3). The difference between the mean AIC coefficients (8) of the models decreased by 60%, relative to the initial value. In addition, the reduced Neumann’s model better approximated experimental data. Therefore, we used it as the basis for the model composition.
We took into account that the considered experimental data were obtained with SKW 6.4 [18] and HeLa [19] cells, which were shown to behave as type I [21] and type II [28] cells, respectively. In this regard, we assumed that:

(A)
initial species concentrations could vary for different cell lines;

(B)
kinetic parameters of all reactions (besides the degradation rate modeled as the function k _{ d } · x _{ aa } ^{2}) have the same values for both cell lines, whereas the value of k _{ d } could be regulated by various entities and, moreover, is dependent on the initial concentration of antiCD95 [18];

(C)
type I and type II cells conform to different reaction chains of caspases3 activation [21].
We constructed the composite model of CD95 and NFκB signaling in the following way. Firstly, according to the assumption (C), we replaced reaction nr15 in the Neumann’s model by a chain of three reactions:
The first reaction of this chain had the same kinetic law as br7*. The other reactions represented br6* and nr15 with kinetics modified using the law of mass action. Such modification of br6* was necessary to get the slow increase of caspase3 concentration experimentally described by Neumann et al.[19]. Modification of nr15 consisted in substitution of C_{casp9} for C_{casp8} .
Secondly, we supplemented the Neumann’s model with reaction of caspase3 inhibition by IAP and evaluated parameters in this reaction together with parameters in (17) using the corresponding data by Neumann et al. and optimization tools of BioUML [29].
Thirdly, we analyzed the changes of the initial concentrations and parameters of the derived model required to reproduce the Bentele’s experimental data fixing levels of procaspases3, 8, cleaved product p43/p41, and caspase8 (Table 4). All the changes, except step 4, agreed with assumptions (A) and (B). To reproduce the species dynamics, we had to increase the initial concentration of procaspase3 in the case of HeLa cells by an order of magnitude.
Finally, we combined the modules of caspase8 and NFκB activation with the modules of caspase9 activation and PARP inactivation (Figure 7). For this purpose, we modified the last two modules based on (17) and refitted their parameters as well as the concentrations mentioned in Table 4, using experimental data by Bentele et al. For better fit we also supplemented the model by degradation reactions of some species (procaspase9, caspase9, DISC:pro8 and DISC:pro8:FLIPS).
The resulting composite model (Figure 8) consists of 30 species (including one virtual species), 38 reactions (including 15 reactions of the species degradation) and 30 kinetic parameters, except for the constant concentration of IKK (Additional file 1: Table 2S, Additional file 1: Table3S, Additional file 1: Table4S). The model showed a good fit between the simulation results and the experimental data (Figures 5 and 6).
Calculation of the mean AIC coefficient for this model revealed that it has the same level of complexity as the reduced models (Table 3). We also noted that reduction of both models did not significantly alter the steadystate concentrations (Additional file 1: Table 5S, Additional file 1: Table6S). However, the composite model has different steadystates, which are more stable according to the mean sensitivities (9) in the cases of SKW 6.4 cells and HeLa cells stimulated with 250 ng/ml of antiCD95 (Additional file 1: Table 7S).
The reduced models are equivalent to the precursor models with respect to their biological predictions
Analyzing the models constructed by Neumann et al. and Bentele et al., we divided predictions made by them into two groups: qualitative and quantitative. The first group concerned the model network and described mechanisms of the proteinprotein interactions. It is this group to which we assigned the experimentally validated Neumann's predictions that processed caspases are not required for NFκB activation, as well as that proapoptotic and NFκB pathways diverge already at DISC. The corresponding network of reactions was preserved in the reduced model. Thus, the prediction remained valid.
The second group of predictions characterized behavior of the models after changing concentrations of some species, such as CD95L, CD95R, procaspase8, and inhibitors cFLIPL, cFLIPS, and IAP. Analyzing the predictions of the models by Neumann et al. and Bentele et al. listed in the Tables 5 and 6 respectively, we concluded that the reduction of the first of them did not alter the species dynamics (Additional file 1: Table 8S). For the second reduced model, we detected some minor changes in the predictions. However, in general, the model behavior remained in a good agreement with the Bentele's experiments (Additional file 1: Table 9S).
Model composition modifies some properties of the precursor models and leads to new predictions
Considering the predictive ability of the composite model, we found that in the case of HeLa cells it was completely preserved (Table 5).
In the case of SKW 6.4 cell line, we estimated the value of degradation rate parameter k_{ d } based on the experimental observations by Bentele et al. for 1–10 ng/ml of antiCD95 (Table 6). When performing simulation experiments of the model for this cell line, we used three different values of k_{ d } depending on whether the initial concentration of CD95L was within the range 1–100 ng/ml, within the range 100–1000 ng/ml or greater than 1000 ng/ml (Additional file 1: Table 3S).
Analyzing the model predictions, we detected differences in the behavior of the Bentele’s and the composite models (Table 6). The first of them describes a threshold mechanism for CD95induced apoptosis implying that this process is completely stopped when CD95L concentration is below the critical value. However, the model predicts a sharp increase of cPARP immediately when the level of CD95L exceeds the threshold (Table 6, № 1). In contrast, the composite model shows a gradual increase of cPARP with increase of the ligand level. To determine the apoptotic threshold in this case, we found concentration of CD95L for which cPARP ratio is equal to 10% of the initial PARP amount [30]. As in the original model, this concentration was in the range of 1–10 ng/ml. Additionally, the models revealed sensitivity of the threshold to the concentration of cFLIP (Table 6, № 2). Both of them predicted the cell death phenotype upon stimulation by 1 ng/ml antiCD95 and the level of cFLIP decreased by ~50%.
The next prediction, which we observed for SKW 6.4 cells, considers a delay of caspase8 activation caused by low concentrations of antiCD95 (Table 6, № 3). The maximal delay predicted by the Bentele’s model was about 2500 min, whereas the composite model detected a much lower value (700–800 min). Analysis of dependence of caspase3 concentration on initial values of IAP and CD95L (Table 6, № 4) also demonstrated differences in the models’ predictions. Thus, low level of IAP (less than 1 nM) in the original model results in complete cell death. However, under the same condition the composite model shows a smooth increase of caspase3 levels with CD95L changing from 0.3 nM to 1000 nM. If the amount of the ligand is less than 0.3 nM, IAP blocks apoptosis completely. In addition, the Bentele’s model predicts that high concentration of IAP prevents a significant increase of caspase3 even for high levels of the ligand, whereas in the composite model high concentration of CD95L leads to cell death.
Limitations of the composite model
We analyzed a set of parametric constraints which allowed us to reduce the precursor models (Additional file 1: Table 10S). Following them, we can recover a detailed description of the investigated process. Connection of the composite model with the original model by Neumann et al. was preserved, whereas with the original model by Bentele et al. it was partially lost since the chains of species interactions were changed for the sake of combining the models together. In particular, the pathway of caspase8 activation in DISC was derived from the Neumann’s model as well as the reaction chain of procaspase9 cleavage was modified. However, following the constraints of Additional file 1: Table 10S, we can complete the composite model with such reactions as Bid truncation by caspase2 and PARP cleavage triggered by caspase7. We can also recover the details of caspase9 activation mediated by cytochrome C and Smac release from mitochondria but with altered kinetics of release. For now, the question of admissibility of such modifications as well as extension of the composite model based on other apoptosis models remains open and is a challenge for further research.
Discussion
In this paper, we considered two approaches to development of mathematical models of cell fate decisions. The first concerns the methodology of model reduction and involves approximation of one model by another one of lower dimension without affecting dynamics of experimentally measured species. The second implies composition of the models and aims at reproducing experimental dynamics of all precursor models.
There are many advantages of working with lowdimensional models [8]. In particular, the researcher has a clear vision of the most important biochemical reactions taking place in the modeled system as well as better understanding of them. Lowdimensional models are easier to analyze and faster to simulate. This helps to save time and enhances productivity. The main limitation of model reduction consists in loss of biological information. However, it should be noted that even if some information (for example, about very slow biochemical reactions) may be lost, it can result in a more clear understanding of the most important interactions and allows focusing on the decisive processes in the model, predictive ability of which is reasonably preserved. Hence, this limitation can be transformed into an advantage.
Model composition aiming at getting a single model from several ones is useful because in such a case a computational biologist is able to investigate the composite model behavior under different conditions that cannot be performed in the precursor models separately. For example, our model allows studying the role of p43FLIP or IAP in the type I SKW 6.4 or type II HeLa cells, respectively, that might become a task for the future work. In other words, we constructed the model that describes pro and antiapoptotic signal transduction in different cell types with reasonable accuracy instead of a couple of different models. Whenever necessary, some reaction chains and parameters can be switched off giving opportunity to simulate a certain type of cells. In addition, the composite model covers experimental data obtained from all precursor models, each of which separately satisfies its own data only.
Model composition sometimes causes modification of some properties of the initial models, resulting in new testable predictions. In our case, such predictions were related to SKW 6.4 cells, and some simulation results were different from the corresponding results of the original Bentele’s model. Nonetheless, the composite model behavior remained in good agreement with experimental data used in modeling by Bentele et al. Thus, the question of what model (original or composite) is more realistic requires further experimental investigation.
One of the questions that can be asked concerns the need of reducing models in order to combine them. An attempt to construct the composite modular model of apoptosis was made in [26]. This attempt revealed multiple conceptual and methodological difficulties. The main obvious obstacles included:

choice of elements in the overlapping parts of different models;

incomparable sets of parameters;

the lack of experimental data, as well as inability to use the data obtained for different cell lines or in different ways (e.g. singlecell or cell culture measurements);

inability to make accurate predictions.
Model reduction allows solving some of these problems. In particular, reducing the number of model elements, we reduce the overlapping parts as well. This may be essential for direct combining of models. In addition, the complexity of the reduced model become comparable with the complexity of available experimental data. Therefore, the risk of model overfitting is decreased.
In the case when two models are directly related (for example, one model was emerged from the other), their composition may be significantly easier in comparison to composition of quite different models. In our work, the models by Bentele et al. and Neumann et al. are not directly related, as it could be expected as these models were constructed in the same research group. For example, they use different reaction chains of caspase8 activation and different values of kinetic parameters in the overlapping reactions.
Another quite useful principle that we used in modeling was modular structure of the developed model. This principle provides flexibility for future extensions. Thus, we are planning to extend the composite model and supply it with modules and data from studies of TRAIL [31–33] and TNFα [34, 35] signaling, apoptosomedependent caspase activation [36] and p53 oscillation system [37]. It is noteworthy that the model by Laussmann et al.[33], describing TRAILinduced activation of caspase8, emerged from the original study by Bentele et al.[18]. This fact may help us in our future work.
Characterising the models used in our work, we can say that we saved our time working with the model by Neumann et al.[19] derived from the BioModels database [27], and spent a lot of time to reproduce the model by Bentele et al.[18] that had not existed in a readytouse format. Thus, we would like to emphasize that for the common benefit, the systematic application of biological standards in modeling (e.g. SBML [38] and SBGN [39]) and depositing the working models in public databases (e.g. BioModels [27]) would significantly facilitate analysis of existing biomathematical models and using them as the base for development of new composite systems.
Finally, we believe that the composite model itself may be useful for further investigation of apoptosis.
Conclusions
Mathematical modeling provides a powerful tool for studying the properties of biological processes. Methods of model reduction allowed us to take a first step towards validation of the modular model of apoptosis [26]. Using these methods, we composed two models describing pathways of CD95 and NFκBsignaling in one without affecting the fit to the experimentally measured dynamics and model predictions. For the model reduction and composition, we used the BioUML software that was extended by the required methods of analysis.
The models by Bentele et al. and Neumann et al. reconstructed in BioUML and represented using SBML format and SBGN notation, as well as their reduced and decomposed versions are available at http://ie.biouml.org/bioumlweb/#de=databases/The%20composite%20model%20of%20CD95%20and%20NFkB%20signaling.
References
 1.
Hlavacek WS: How to deal with large models?. Mol Syst Biol. 2009, 5: 240
 2.
Gorban AN, Radulescu O, Zinovyev AY: Asymptotology of Chemical Reaction Networks. Chemical Engineering Science. 2009, 65: 23102324.
 3.
Gorban AN, Karlin IV, Zinovyev AY: Constructive methods of invariant manifolds for kinetic problems. Physics Reports. 2004, 396: 197403.
 4.
Klonowski W: Simplifying principles for chemical and enzyme reaction kinetics. Biophys Chem. 1983, 18 (2): 7387.
 5.
Calzone L, Tournier L, Fourquet S, Thieffry D, Zhivotovsky B, Barillot E, Zinovyev A: Mathematical modelling of cellfate decision in response to death receptor engagement. PLoS Comput Biol. 2010, 6 (3): e1000702
 6.
Liebermeister W, Baur U, Klipp E: Biochemical network models simplified by balanced truncation. FEBS J. 2005, 272 (16): 40344043.
 7.
Bruggeman FJ, Westerhoff HV, Hoek JB, Kholodenko BN: Modular response analysis of cellular regulatory networks. J Theor Biol. 2002, 218 (4): 507520.
 8.
Radulescu O, Gorban AN, Zinovyev A, Noel V: Reduction of dynamical biochemical reactions networks in computational biology. Frontiers in genetics. 2012, 3: 131
 9.
Kolpakov FA, Valeev IT, Tolstyh NI, Kisele I, Kondrakhin YV, Kutumova EO, Yevshin IS: BIoUML  open source Integrated platform for building virtual cell and virtual physiological 1 human. Virtual Biology. in press, DOl: 10.127041vb1e12
 10.
Calzone L, Fages F, Soliman S: BIOCHAM: an environment for modeling biological systems and formalizing experimental knowledge. Bioinformatics. 2006, 22 (14): 18051807.
 11.
Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N, Singhal M, Xu L, Mendes P, Kummer U: COPASI — a COmplex PAthway SImulator. Bioinformatics. 2006, 22: 30673074.
 12.
Naldi A, Berenguier D, Fauré A, Lopez F, Thieffry D, Chaouiya C: Logical modelling of regulatory networks with GINsim 2.3. Biosystems. 2009, 97 (2): 13413.
 13.
Zinovyev A, Morozova N, Nonne N, Barillot E, HarelBellan A, Gorban AN: Dynamical modeling of microRNA action on the protein translation process. BMC Syst Biol. 2010, 4: 13
 14.
Morozova N, Zinovyev A, Nonne N, Pritchard LL, Gorban AN, HarelBellan A: Kinetic signatures of microRNA modes of action. RNA. 2012, 18 (9): 16351655.
 15.
Quaiser T, Dittrich A, Schaper F, Mönnigmann M: A simple workflow for biologically inspired model reduction – application to early JAKSTAT signaling. BMC Syst Biol. 2011, 5: 30
 16.
Radulescu O, Gorban AN, Zinovyev A, Lilienbaum A: Robust simplifications of multiscale biochemical networks. BMC Syst Biol. 2008, 2: 86
 17.
Conzelmann H, SaezRodriguez J, Sauter T, Bullinger E, Allgöwer F, Gilles ED: Reduction of mathematical models of signal transduction networks: simulationbased approach applied to EGF receptor signalling. Syst Biol. 2004, 1 (1): 159169.
 18.
Bentele M, Lavrik I, Ulrich M, Stößer S, Heermann DW, Kalthoff H, Krammer PH, Eils R: Mathematical modeling reveals threshold mechanism in CD95induced apoptosis. J Cell Biol. 2004, 166 (9): 839851.
 19.
Neumann L, Pforr C, Beaudouin J, Pappa A, Fricker N, Krammer PH, Lavrik IN, Eils R: Dynamics within the CD95 deathinducing signaling complex decide life and death of cells. Mol Syst Biol. 2010, 6: 352
 20.
Krammer PH, Rüdiger A, Lavrik IN: Life and death in peripheral T cells. Nat Rev Immunol. 2007, 7: 532542.
 21.
Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME: Two CD95 (APO1/Fas) signaling pathways. EMBO J. 1998, 17 (6): 16751687.
 22.
Choi J, Yang KW, Lee TY, Lee SY: New timescale criteria for model simplification of bioreaction systems. BMC Bioinformatics. 2008, 9: 338
 23.
Wei J, Kuo JC: A lumping analysis in monomolecular reaction systems: Analysis of the exactly lumpable system. Ind Eng Chem Fundam. 1969, 8: 114123.
 24.
Akaike H: A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974, 19 (6): 716723.
 25.
Schilling M, Maiwald T, Hengl S, Winter D, Kreutz C, Kolch W, Lehmann WD, Timmer J, Klingmüller U: Theoretical and experimental analysis links isoformspecific ERK signaling to cell fate decisions. Mol Syst Biol. 2009, 5: 334
 26.
Kutumova EO, Kiselev IN, Sharipov RN, Lavrik IN, Kolpakov FA: A modular model of the apoptosis machinery. Adv Exp Med Biol. 2012, 736 (2): 235245.
 27.
Le Novère N, Bornstein B, Broicher A, Courtot M, Donizelli M, Dharuri H, Li L, Sauro H, Schilstra M, Shapiro B, Snoep JL, Hucka M: BioModels Database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems. Nucleic Acids Res. 2006, 34: D689D691.
 28.
Engels IH, Stepczynska A, Stroh C, Lauber K, Berg C, Schwenzer R, Wajant H, Jänicke RU, Porter AG, Belka C, Gregor M, SchulzeOstho K, Wesselborg K: Caspase8/FLICE functions as an executioner caspase in anticancer druginduced apoptosis. Oncogene. 2000, 19: 45634573.
 29.
Kutumova EO, Ryabova AS, Valeev TF, Kolpakov FA: BI0UML plugin for nonlinear parameter estimation using multiple experimental data. Virtual Biology. 1: in press. DOl: 10.127041vb1e10
 30.
Gaudet S, Spencer SL, Chen WW, Sorger PK: Exploring the contextual sensitivity of factors that determine celltocell variability in receptormediated apoptosis. PLoS Comput Biol. 2012, 8 (4): e1002482
 31.
Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK: Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell. 2008, 30 (1): 1125.
 32.
Albeck JG, Burke JM, Spencer SL, Lauffenburger DA, Sorger PK: Modeling a snapaction, variabledelay switch controlling extrinsic cell Death. PLoS Biol. 2008, 6 (12): e299
 33.
Laussmann MA, Passante E, Hellwig CT, Tomiczek B, Flanagan L, Prehn JH, Huber HJ, Rehm M: Proteasome inhibition can impair caspase8 activation upon submaximal stimulation of apoptotic tumor necrosis factorrelated apoptosis inducing ligand (TRAIL) signaling. J Biol Chem. 2012, 287 (18): 1440214411.
 34.
Rangamani P, Sirovich L: Survival and apoptotic pathways initiated by TNFalpha: modeling and predictions. Biotechnol Bioeng. 2007, 97 (5): 12161229.
 35.
Cho KH, Shin SY, Lee HW, Wolkenhauer O: Investigations into the analysis and modeling of the TNFαmediated NFκBsignaling pathway. Genome Res. 2003, 13: 24132422.
 36.
Rehm M, Huber HJ, Dussmann H, Prehn JH: Systems analysis of effector caspase activation and its control by Xlinked inhibitor of apoptosis protein. EMBO J. 2006, 25 (18): 43384349.
 37.
Hamada H, Tashima Y, Kisaka Y, Iwamoto K, Hanai T, Eguchi Y, Okamoto M: Sophisticated framework between cell cycle arrest and apoptosis induction based on p53 dynamics. PLoS One. 2008, 4 (3): e4795
 38.
Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, CornishBowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le Novère N, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED: The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics. 2003, 19 (4): 524531.
 39.
Le Novère N, Hucka M, Mi H, Moodie S, Schreiber F, Sorokin A, Demir E, Wegner K, Aladjem MI, Wimalaratne SM, Bergman FT, Gauges R, Ghazal P, Kawaji H, Li L, Matsuoka Y, Villéger A, Boyd SE, Calzone L, Courtot M, Dogrusoz U, Freeman TC, Funahashi A, Ghosh S, Jouraku A, Kim S, Kolpakov F, Luna A, Sahle S, Schmidt E: The Systems Biology Graphical Notation. Nat Biotechnol. 2009, 27 (8): 735741.
Acknowledgements
This work was supported by FP6 grant 037590 "Net2Drug", FP7 grant 090107 "LipidomicNet", EU FP7 (project APOSYS) and Agence Nationale de la Recherche (project ANR08SYSC003 CALAMAR). AZ is a member of the team “Systems Biology of Cancer,” Equipe labellisée par la Ligue Nationale Contre le Cancer.
Author information
Affiliations
Corresponding author
Additional information
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
EK performed reduction, integration and analysis of the apoptosis models. AZ coordinated the model reduction part of the study. RS and FA coordinated the study of the apoptosis machinery. FA also led implementation of the analysis toolbox in the BioUML software. All authors have participated in writing and editing the manuscript, as well as read and approved the final manuscript.
Electronic supplementary material
Table 2S.
Additional file 1: Table 1S: Notations of parameters used in the paper and in the original models. Table of all reactions (excepting degradation) and rate constants in the composite model. Table 3S. Table of degraded species and kinetic laws of degradation in the composite model. Table 4S. Table of nonzero initial concentrations in the composite model. Table 5S. Steady state analysis of the Bentele’s model and the composite model. Species. Table 6S. Steady state analysis of the Neumann’s model and the composite model, Table 7S. Calculation of the mean sensitivity for the investigated apoptosis models. Table 8S. Analysis of predictions regarding apoptosis in HeLa cells as formulated by Neumann et al. Table 9S. Predictions of the models for SKW 6.4 cells. Table 10S. Parametric constraints of the models by Bentele et al. and Neumann et al. (PDF 544 KB)
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Kutumova, E., Zinovyev, A., Sharipov, R. et al. Model composition through model reduction: a combined model of CD95 and NFκB signaling pathways. BMC Syst Biol 7, 13 (2013). https://0doiorg.brum.beds.ac.uk/10.1186/17520509713
Received:
Accepted:
Published:
DOI: https://0doiorg.brum.beds.ac.uk/10.1186/17520509713
Keywords
 Model Reduction
 Composite Model
 Ordinary Differential Equation
 Model Composition
 BioModels Database